Business context and reporting period
Enanta Pharmaceuticals, Inc. is an R&D-focused biotechnology company developing treatments for viral infections and liver diseases. This unaudited Form 10-Q covers the three and nine months ended June 30, 2016 (fiscal Q3 and year to date), compared with the same 2015 periods. Its principal commercial revenue is royalties and milestone payments from AbbVie’s HCV collaboration; Enanta’s own programs include HCV, NASH, HBV and RSV.
Key financial metrics
Amounts are in millions of dollars except per-share data. Balance-sheet comparisons are June 30, 2016 versus September 30, 2015.
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Revenue | $13.98 | $11.60 | $75.43 | $146.46 |
| Operating expenses | $15.07 | $9.90 | $41.49 | $25.99 |
| Operating income (loss) | $(1.09) | $1.70 | $33.94 | $120.47 |
| Net income (loss) | $(1.08) | $2.42 | $23.47 | $73.18 |
| Diluted EPS | $(0.06) | $0.13 | $1.22 | $3.80 |
| Operating cash flow | Not presented separately | Not presented separately | $37.94 | $79.05 |
- Q3 revenue was entirely AbbVie royalties. Nine-month revenue included $44.85 million of royalties, $30.00 million of milestones and $0.58 million of NIAID contract revenue.
- Q3 operating margin was approximately -7.8%; nine-month operating margin was approximately 45.0%. Nine-month profitability included a $30 million milestone and is not a recurring-margin indicator.
- At June 30, cash and cash equivalents were $24.79 million, and marketable securities were $219.87 million; together these totaled $244.66 million. Current assets were $241.79 million and current liabilities $9.57 million.
- Total liabilities were $12.93 million. The company reported no debt outstanding; liabilities included $1.24 million warrant liability, $0.16 million preferred stock and lease-related obligations.
- Nine-month investing cash flow was $(37.52) million, primarily reflecting securities purchases and maturities and $4.32 million in property and equipment purchases. Financing cash flow was $2.64 million.
Material changes versus prior comparable periods
- Q3 revenue increased 20% year over year as royalties rose to $13.98 million from $11.39 million; the prior-year quarter also included $0.21 million of NIAID revenue.
- Q3 R&D expense increased 72% to $10.79 million, and G&A rose 18% to $4.28 million, resulting in an operating loss versus operating income a year earlier. Management attributed higher R&D spending to advancing clinical and preclinical programs, hiring, facility expansion and external research costs.
- Nine-month revenue fell 48% year over year, primarily because milestone revenue declined to $30 million from $125 million. Royalties increased to $44.85 million from $19.74 million, which management attributed to higher AbbVie regimen sales.
- Nine-month R&D expense rose 79% to $28.96 million. Net income declined to $23.47 million from $73.18 million, reflecting lower milestone revenue and higher operating expenses.
- Nine-month operating cash flow fell by $41.11 million, principally due to lower AbbVie cash receipts and increased R&D spending, partly offset by lower income tax payments.
Outlook, commentary and risks
- Management said existing cash, cash equivalents and marketable securities should fund anticipated requirements for the foreseeable future, while cautioning that this is forward-looking and actual needs may differ. No specific financial guidance range is provided.
- Management expected R&D spending to continue increasing as EDP-494 advances in clinical development, EDP-305 proceeds toward planned clinical trials in the second half of calendar 2016, and HBV and RSV research progresses. The company intended to advance a candidate in at least one of HBV or RSV into the clinic in calendar 2017.
- Revenue and near-term financial performance remain substantially dependent on AbbVie’s development and commercialization decisions, paritaprevir royalties and potential ABT-493 milestones and royalties. Up to $80 million in additional collaboration milestones were available subject to specified approvals.
- Key uncertainties include intense HCV competition and pricing/reimbursement pressure; uncertain demand and royalty levels; clinical, safety and regulatory risks; dependence on third-party collaborators, manufacturers and clinical vendors; and potential need for financing if collaboration revenue weakens or development costs rise.
- The company reported no pending or threatened litigation and no material change in commitments and contingencies during the nine-month period. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- AbbVie’s current and prospective HCV product sales, reimbursement, competitive position and resulting royalty calculations.
- Progress, trial results, costs and timing for EDP-494, EDP-305, and the HBV and RSV programs against management’s stated development plans.
- The sustainability of cash resources as R&D spending rises, especially if milestone receipts or paritaprevir royalties decline.
- Whether any further AbbVie milestone payments are achieved and the potential timing and terms of the remaining eligible milestones.
- Clinical, regulatory, intellectual-property and manufacturing developments that could delay or prevent development or commercialization.